Ixogen
Business Services · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
United KingdomWebsite
www.ixogen.comRevenue
<$5 MillionIndustry
About Ixogen
Is Ixogen your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Ixogen has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Ixogen recently announced quarterly report
Product Launch: Get notified when Ixogen launches new products
Click to see if Ixogen had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Ixogen
Website visits: Recent activity has been detected on your website
Ixogen, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Ixogen has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Ixogen is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Ixogen
Compare insights from companies similar to Ixogen, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Ixogen
Company Profile Activity
Activity Insights
Ixogen is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Ixogen is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Ixogen.
Ixogen Tech Stack
A closer look at the technologies used by Ixogen
Top Business Services Companies
Frequently Asked Questions Regarding Ixogen
IXOGEN Ltd is a UK-based biotechnology company focused on developing safe and effective oncolytic virus therapies for cancer treatment. Utilizing a patented multi-modality delivery system, the company transforms common oncolytic viruses into cancer-selective agents. Their technology employs genetically modified adenoviruses to specifically target a... Read More